Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

  • receive the eCopy two days prior to the printed edition.
  • can partake in our online MCQs.
  • can enter our online sports quiz.


Medicalindependent.ie is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

You are reading 1 of 2 free-access articles allowed for 30 days

RCSI clinical trial reveals new treatment option for Covid-19

By Reporter - 11th Mar 2022 | 246 views

Microscopic illustration of the spreading 2019 corona virus that was discovered in Wuhan, China. The image is an artisic but scientific interpretation, with all relevant surface details of this particular virus in place, including Spike Glycoproteins, Hemagglutinin-esterase, E- and M-Proteins and Envelope.

A clinical trial conducted by researchers from the RCSI and Beaumont Hospital, Dublin, has indicated an effective treatment for critically ill Covid-19 patients.

The study, published in Med, investigates the effects of using an anti-inflammatory protein, alpha-1 antitryspin (AAT), to treat Covid-19 patients who have progressed to acute respiratory distress syndrome (ARDS).

ARDS is a highly inflammatory state hallmarked by airway damage, respiratory failure and increased risk of death. Treatment options for Covid-19 patients who have ARDS are particularly limited.

AAT is a naturally occurring human protein produced by the liver and released into the bloodstream which normally acts to protect the lungs from the destructive actions of common illnesses.

In this randomised controlled trial, AAT that had been purified from the blood of healthy donors was administered to patients with COVID-19-associated ARDS, with the aim of reducing inflammation.

The results indicated that treatment with AAT led to decreased inflammation after one week. The study also found that the treatment was safe and well tolerated, and did not interfere with patients’ ability to generate their own protective response to Covid-19.

This discovery suggests a potentially important role for AAT in the treatment of ARDS and other inflammatory diseases associated with Covid-19.

The study’s co-lead author, Dr Oliver McElvaney from the RCSI Department of Medicine and Beaumont Hospital, commented on these novel findings: “We know that patients who are critically ill with Covid-19 are more prone to developing severe inflammation throughout the body, with a disproportionately high rate of progression to ARDS and other serious respiratory issues. We think AAT might be able to provide some protection against the more harmful types of inflammation that arise in severe COVID-19 and other conditions with a similar inflammatory profile.”

Ms Natalie McEvoy, Senior Clinical Research Nurse in the Department of Critical Care and Anaesthesia at the RCSI and Beaumont Hospital and the paper’s co-lead author, commented: “This study is the first randomized control trial of AAT for acute respiratory distress syndrome, the first randomized control trial of AAT in the intensive care unit and the first such trial of a Covid-19 therapeutic in Ireland.”

Senior author on the paper, Prof Ger Curley from the RCSI Department of Anaesthetics and Critical Care and Beaumont Hospital, noted the national significance of the study: “It is only through clinical trials we will be able to determine if new treatments are effective and safe in critically ill patients with COVID-19. This study is the first Irish-led clinical trial of a medicine for COVID-19. The rationale for the study, its design and the recruitment of critically ill patients was all carried out by researchers from RCSI, Beaumont Hospital and St James’s Hospital on patients here in Ireland.”

Prof Gerry McElvaney, RCSI Department of Medicine and Beaumont Hospital, and senior author on the paper, commented: “These early results are encouraging, and will we hope form the basis for a larger trial to see how much of an effect reducing inflammation using AAT has on clinical outcomes such as mortality.”

The study was a collaboration between RCSI University of Medicine and Health Sciences, Beaumont Hospital, Dublin and St James’s Hospital, Dublin.

Leave a Reply

Latest
Latest Issue
The Medical Independent 9th May 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read